Novavax is a late-stage biotechnology company dedicated to improving health globally through the discovery, development, and commercialization of innovative vaccines.

Biotechnology

Pharmaceutical

Novavax

John A. Herrmann III is the EVP, Chief Legal Officer & Corporate Secretary at [Novavax](/org/novavax). Prior to their current role, John served as the Senior Vice President, General Counsel and Corporate Secretary at [Novavax](/org/novavax) from April 2010 to June 2020. In this role, they were responsible for [Novavax](/org/novavax)’s legal affairs including its patent portfolio, transactional matters, and public securities filings, as well as attending to all the duties of corporate secretary.

From December 2007 to April 2010, John served as the General Counsel at Ore Pharmaceuticals where they were responsible for all legal matters of a small, publicly-traded (NASDAQ) biotech company.

From March 2005 to December 2007, John served as the Deputy General Counsel at Gene Logic. In this role, they were responsible for providing legal support to all business units of the company, with a focus on intellectual property, corporate governance, and securities law compliance.

From January 2001 to February 2005, John served as the Senior Counsel at Celera Genomics where they were responsible for commercial contracts, M&A, and other complex legal matters.

From January 1993 to December 2000, John served as the Senior Corporate Counsel at Baxter Healthcare. In this role, they were responsible for a variety of legal matters including mergers and acquisitions, commercial contracts, compliance, and litigation.

John A. Herrmann III's educational career began at Lake Forest High School. John then went on to study history and political science at [Brown University](/org/brown-university), where they earned their BA. Finally, they attended the University of Illinois College of Law, earning their JD.

John A. Herrmann III reports to Stanley C. Erck, President & CEO. A direct report to John A. Herrmann III is and Troy Morgan - SVP, Chief Compliance Officer. They work with Biegie Lee - SVP, CIO, Gale E. Smith - SVP, Discovery & Pre-clinical Research & Chief Scientist, and Rick Crowley - EVP, COO.

John A. Herrmann III

From 2010 to 2013, Mr. Rodgers was co-founder, Executive Vice President, Chief Financial Officer, Secretary, and Treasurer of TESARO, Inc., a biopharmaceutical company that was acquired in January 2019 by GSK for over $5 billion. From 2009 to 2010, Mr. Rodgers served as the Chief Financial Officer and Senior Vice President of Abraxis BioScience, Inc., a biotechnology company that was acquired by Celgene for $2.9 billion. From 2004 to 2008, Mr. Rodgers served as Senior Vice President, Controller and Chief Accounting Officer of MGI PHARMA, Inc., a biopharmaceutical company that was acquired in January 2008 by Eisai for $3.9 billion.

Mr. Rodgers currently serves on the boards of directors and as the chair of the audit committee and member of the compensation committee of Ocuphire Pharma, Inc., Sagimet Biosciences, Inc., and Ardelyx, Inc.

Mr. Rodgers holds a Bachelor of Science degree in Financial Accounting from St. Cloud State University and a Master of Business Administration in Finance from the University of Minnesota, Carlson School of Business.

Richard Rodgers

Dr. Kahsai is senior vice president of Global Quality Assurance and Quality Control, responsible for setting strategic direction and leading the quality assurance and quality control organizations. He joined Novavax in 2021, bringing more than 27 years of global experience in QualityAssurance, Quality Control, CMC Regulatory Support, Analytical Development and operational leadership. Prior to joining Novavax, he served as senior vice president, QA/QC/Bio-Analytical/CMC at Caelum Biosciences, where he implemented robust quality systems and managed CRO and CMO relationships, and process development from pre-clinical to clinical/commercialization. Previously, Dr. Kahsai held roles of increasing responsibility at Eli Lilly and Company from 2006-2018, where he most recently served as vice president, Quality Control, Analytical Program, and regulatory CMC support. Dr. Kahsai also worked for both Cardinal Health Sterile Technologies Division, and Baxter Healthcare earlier in his career. Dr. Kahsai holds a bachelor degree in chemistry, Master of Science degrees in analytical chemistry from South Dakota State University and in biochemistry from University of Nebraska, and a PhD in biochemistry and molecular biology from University of Kansas Medical School.

Michael Kahsai

Dr. Walker is senior vice president, deputy chief medical officer with responsibility for day-to-day medical and clinical activities at Novavax. A specialist in internal, pulmonary and critical care medicine, Dr. Walker has more than 30 years of experience in drug and vaccine development within the private and public sectors. He joined Novavax from Meissa Vaccines, Inc., where he led the development of RSV and COVID-19 vaccines. Prior to Meissa, Dr. Walker was Chief Medical Officer and Director of the Division of Clinical Development at the Biomedical Advanced Research and Development Authority (BARDA) in the U.S. Department of Health and Human Services. He and his team provided expertise to medical countermeasure programs, including Operation Warp Speed for COVID-19 vaccines and therapeutics, and to federal emergency responses to Zika, Ebola and influenza epidemics. Dr. Walker earned his doctor of medicine degree from the University of Maryland. He completed his internal medicine training at the George Washington University and completed his fellowship in pulmonary and critical care medicine at the University of Pennsylvania.

Robert Walker

Dr. Cacciuttolo is senior vice president of process and analytical development with responsibility for ensuring the quality and safety of Novavax’ vaccine candidates. He brings more than three decades of biochemical engineering experience to Novavax and has successfully developed commercial processes for many products.

Prior to joining Novavax in July 2020, Dr. Cacciuttolo served as head of manufacturing at Nosocomial Vaccine Corporation, chief operating officer at PathoVax LLC, and managing director of Batavia Biosciences. Earlier in his career, he held positions of increasing responsibility at MedImmune LLC, Medarex, Percivia LLC and Tetragenetics, Inc.

Dr. Cacciuttolo received a bachelor’s degree in biochemical engineering from Pontifical Catholic University of Valparaíso and a doctorate in biochemical engineering from the University of Maryland, Baltimore.

Marco Cacciuttolo

Dr. Ukwu is senior vice president, and chief regulatory and quality officer with responsibility for leading global regulatory strategy and execution as well as the quality assurance function. Dr. Ukwu joined [Novavax](/org/novavax) in January 2021, bringing more than two decades of experience in regulatory affairs and quality and successfully bringing numerous products through regulatory approval. Prior to joining [Novavax](/org/novavax), Dr. Ukwu was chief regulatory officer and global head of quality and regulatory at Otsuka Pharmaceuticals, where she led the regulatory and quality organizations with a focus on compliance excellence, inspection readiness and engagement with health authorities and regulatory agencies. She previously held senior leadership roles at PPD as senior vice president and head of Global Regulatory Affairs where she had responsibilities for regulatory services across all PPD lines of business; Wyeth Pharmaceuticals, Inc.(Pfizer), where she was vice president, regulatory affairs with responsibility that spanned vaccines, biologics, and pharmaceuticals and across all regions, and at Merck & Co., Inc., as head of vaccine regulatory development, vice president of global regulatory affairs and global regulatory policy. Dr. Ukwu holds medical and surgical degrees from the University of Jos School of Medicine in Nigeria, and completed internal medicine residency at University of Tennessee, Baptist Hospital and infectious diseases fellowship at Vanderbilt University Medical Center.

Henrietta Ukwu

Seth Toback is the current Senior Vice President, Global Medical Affairs at [Novavax](/org/novavax). Prior to this, they worked as the Vice President, Global Medical Affairs at [bioMérieux](/org/biomerieux-sa) from January 2018 to July 2020. In this role, they managed a team of 11 international researchers dedicated to designing and executing all global post-marketing clinical trials. Seth was also responsible for overseeing all publication functions, health-economics and investigator-initiated trials. From June 2017 to January 2018, they worked as the Senior Medical Director, Clinical Research at [United Therapeutics](/org/united-therapeutics) where they lead physician on several phase 3 clinical trials in the therapeutic area of Pulmonary Hypertension. In March 2016 to June 2017, they worked as the Senior Medical Director, Medical Affairs at [PRA Health Sciences](/org/pra-health-sciences) and from August 2012 to December 2016, they worked as the Director, Clinical Research Respiratory/Inflammation at [Gilead Sciences](/org/gilead-sciences).

Seth Toback has a Master of Medical Management from Carnegie Mellon University, a Board Certification from the Children's Hospital of Pittsburgh, a Doctor of Medicine from Tufts University School of Medicine, and a BS in Physiology from [McGill University](/org/mcgill-university).

Their manager is Stanley C. Erck, President & CEO. Seth Toback works with Gale E. Smith - SVP, Discovery & Pre-clinical Research & Chief Scientist, Biegie Lee - SVP, CIO, and Jim Kelly - EVP, CFO.

Seth Toback

Mr. Rosen is senior vice president of commercial strategy with responsibility for leading commercial strategy efforts instrumental to ensuring future patient access to Novavax vaccines. Mr. Rosen joined Novavax in 2015 as vice president of market access and policy and was named vice president of commercial strategy in June 2018. He came to Novavax with more than 20 years of industry, legal, and patient advocacy experience with the vast majority engaged in government affairs, advocacy, reimbursement, and policy work. Prior to Novavax, Mr. Rosen was most recently the chief policy, advocacy and patient access officer for the Leukemia Lymphoma Society, where he oversaw all legislative and regulatory efforts and the delivery of patient services nationwide; prior to that, he developed and ran the government affairs, policy, and alliance development functions for MedImmune. Mr. Rosen currently serves as chair of the board of directors of Learning Undefeated, a nonprofit that provides STEM education and workforce development to underserved communities. Mr. Rosen received a bachelor of arts degree in history and psychology from Tufts University and a juris doctorate from Hofstra University School of Law.

Brian Rosen

Dr. Hahn is senior vice president of CMC for NanoFlu with responsibility for leading all CMC activities for the NanoFlu program. Dr. Hahn has 28 years of commercial vaccine and antibody manufacturing experience and a proven track record with clinical and commercial products, process innovation, technology transfer, facility start-up, GMP compliance, and regulatory inspections. Dr. Hahn joined Novavax in June 2011 as senior vice president of manufacturing and process development and was later named senior vice president of global manufacturing operations with responsibility for production sites in the United States and Europe. Prior to joining Novavax, he was vice president of antibody manufacturing and later vice president of vaccine manufacturing at MedImmune, LLC, with responsibilities for sites in the United States and Europe. Prior to MedImmune, he spent more than 15 years in vaccine manufacturing with Merck & Co. Dr. Hahn received a bachelor of science degree in chemical engineering from Lehigh University and a master of science and a doctorate degree in chemical engineering from Stanford University.

Timothy J. Hahn

Mr. Wilson is executive vice president and NanoFlu general manager with responsibility for leading the efforts to advance NanoFlu through global licensure. Mr. Wilson joined [Novavax](/org/novavax) in 2011 as senior vice president, business development, and most recently was responsible for global business development, quality, and program management functions across the company’s entire pipeline. Prior to joining [Novavax](/org/novavax) in November 2011, Mr. Wilson was most recently the chief financial officer at [Supernus Pharmaceuticals](/org/supernus-pharmaceuticals). He was previously senior vice president, chief financial officer, and general counsel of Iomai Corporation, which was acquired in 2008 by Intercell AG, during which time he successfully negotiated a $128 million government contract with the Office of Biomedical Research and Development Authority (BARDA) at the US Department of Health and Human Services. Mr. Wilson was also the acting general counsel of North American Vaccine, Inc. until its acquisition by Baxter International in 2000. Mr. Wilson received a bachelor of arts degree in history from [Princeton University](/org/princeton) and a master degree in business administration and a juris doctorate from the [University of Virginia](/org/university-of-virginia).

Russell P. Wilson

Mr. Kelly is executive vice president, chief financial officer (CFO) and treasurer with responsibility for finance and information technology. He brings more than 25 years of industry experience in both commercial and clinical-stage companies to Novavax.

He joins Novavax from Supernus Pharmaceuticals, where he served as CFO. Previously, he spent 10 years at Vanda Pharmaceuticals, where he was CFO and treasurer from 2010-20. From 2000-10, Mr. Kelly served in finance roles of increasing responsibility at MedImmune (now AstraZeneca) and Biogen, most recently as the Vice President and Controller of MedImmune. 

Mr. Kelly previously was a member of the corporate finance team at Aetna responsible for mergers and acquisitions and treasury management, and with Janssen, a division of Johnson & Johnson. He holds a Master of Business Administration from Cornell University, a Bachelor of Science in Business Administration from the University of Vermont and is a CFA charterholder.

Jim Kelly

Rick Crowley was namee [Novavax](/org/novavax)'s Chief Operations Officer in December, 2020.

Prior to joining [Novavax](/org/novavax), Mr. Crowley was Executive Vice President, Technical Operations for TerSera Pharmaceuticals, where he was responsible for technical support as well as development and strategy for the company’s products, created the initial quality systems, and managed all CMC activities. He served as Senior Vice President, Operations and Quality Assurance for Crealta Pharmaceuticals 2014-2016, where he led all aspects of the supply chain function, managed suppliers and testing, and held responsibility for the management of Regulatory Affairs. Previously, he held the role of Co-President and Chief Operating Officer at Savient Pharmaceuticals, with responsibility for Commercial Operations, Clinical Affairs, Manufacturing/Technical Operations, Regulatory Affairs, Quality Assurance, Quality Control, Project Management, Logistics and Planning. Earlier in his career he held roles of increasing responsibility at ImClone Systems, Incorporated and BASF Bioresearch Corp.

Mr. Crowley earned a Bachelor of Science degree in chemistry from [Denison University](/org/denison-university) and a Master of Science in chemical engineering from the [University of Pennsylvania](/org/university-of-pennsylvania).

Rick Crowley

Mr. Morgan joined [Novavax](/org/novavax) from EMD Serono, Inc., where he was Chief Compliance Officer, responsible for building a global corporate compliance program that supported a broad range of therapies. Previously, he served in senior leadership roles at Merck KGaA, [Sanofi](/org/sanofi), and [Biogen](/org/biogen). At the [Biogen](/org/biogen) spinout Bioverativ, he was responsible for the development, implementation and management of the global compliance program. He holds a Master of Laws from [Pepperdine University](/org/pepperdine-university), Juris Doctorate from Jones School of Law, [Faulkner University](/org/faulkner-university) and a Bachelor of Science from Troy State University.

Mr. Morgan oversees the strategic direction of the company's comprehensive compliance program in a newly created role, which helps to ensure that all respective requirements are met across the organization.

Troy Morgan

Sven Andréasson is the SVP of Corporate Development at [Novavax](/org/novavax). Prior to this, they served as a member of the Board of Directors for Immunicum AB from January 2014 to December 2016. Sven has also held positions as the Chair of the Board of Directors for XImmune AB, CEO of Isconova AB, and CEO of Beta-Cell NV. In addition, they have served on the Board of Directors for TiGenix from January 2003 to December 2011.

Sven Andréasson attended the [Stockholm School of Economics](/org/stockholm-school-of-economics).

Their manager is Jim Kelly, EVP, CFO. Some of their coworkers include Silvia Taylor - SVP, Investor Relations & Corporate Affairs.

Sven Andréasson

Stanley C. Erck is the President and CEO of [Novavax](/org/novavax). Stanley has over 25 years of experience in the biotechnology industry, with a focus on immunology, HIV, autoimmune disease, and organ transplant rejection.

Stanley began their career in 1983 as the Vice President of Corporate Development for Integrated Genetics Inc. Stanley then became the CEO of Procept Biotechnology Corporation in 1988, where they led the company for 10 years. In 1999, they became the CEO of PHT Corporation, a privately held company developing an electronic data capture platform for clinical trial data. Stanley served as the CEO of Iomai Corporation from 2000 to 2008. In 2010, they became the CEO of [BioCryst Pharmaceuticals](/org/biocryst-pharmaceuticals). Stanley has been the President and CEO of [Novavax](/org/novavax) since 2012.

Stanley C. Erck has a MBA from The University of Chicago Booth School of Business with a focus in economics and finance.

Some individuals on their team include Raburn Mallory - SVP, Clincial Development, Biegie Lee - SVP, CIO, and Jim Kelly - EVP, CFO.

Stanley C. Erck

Dr. Smith is senior vice president of discovery and pre-clinical research and chief scientist, with responsibility for oversight of discovery, and managing scientific, technological and research operations at [Novavax](/org/novavax). Dr. Smith joined [Novavax](/org/novavax) in January 2004 as vice president of vaccine development, where he oversaw the company's vaccine technology group. He led the development of [Novavax](/org/novavax)’ core vaccine technology used in the development of nanoparticle vaccines for respiratory syncytial virus, influenza, Ebola, and coronaviruses, including SARS, MERS and SARS-CoV-2, which causes COVID-19. Previously, Dr. Smith was chief scientific officer at Protein Sciences Corporation, responsible for leading the scientific team that developed the first human immunodeficiency virus (HIV) vaccine candidate approved by the FDA for testing in the U.S., and the first recombinant influenza vaccine, Flublok™. He received his Bachelor of Science in biology from the [University of North Dakota](/org/university-of-north-dakota) and a doctorate in microbiology from [Texas A&M University](/org/texas-a-m-university).

Gale E. Smith

Mr. Alton joined the [Novavax](/org/novavax) board of directors in 2020. He spent more than 20 years at [Gilead Sciences](/org/gilead-sciences), where he served in an array of leadership roles across a portfolio of responsibilities. From January 2019 until March 2019, Mr. Alton was Gilead’s interim chief executive officer. Prior to that, he was the company’s chief patient officer, responsible for Gilead’s government affairs, public affairs, patient outreach, and engagement initiatives, as well as efforts to facilitate access to its medicines around the world. During his tenure at Gilead, his wide-ranging roles included leadership of commercial operations in Europe, Asia, Latin America, and Africa, as well as government affairs, public affairs, and global medical affairs. He also served as general counsel and chief compliance officer. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP, where he specialized in corporate finance transactions for healthcare and information technology companies. Mr. Alton is a member of the board of directors of [Corcept Therapeutics](/org/corcept-therapeutics), Enochian Biosciences, and several non-profit organizations, including Black Women’s Health Imperative, AIDSVu, and the Boys and Girls Clubs of Oakland. Mr. Alton received a bachelor’s degree in legal studies from the University of California at Berkeley and a law degree from [Stanford University](/org/stanford).

Gregg Alton

Mr. Trizzino is executive vice president, chief business officer, chief commercial officer and interim chief financial officer with responsibility for global commercial strategy and execution and oversight of IT, investor and public relations, and corporate affairs. He has broad experience in publicly held companies and in vaccines, with previous roles overseeing commercialization, policy, strategy, business development, financing, and investor and public relations. Since rejoining [Novavax](/org/novavax) in 2014, he has held roles of increasing responsibility, including chief financial officer and senior vice president of commercial operations. Mr. Trizzino served as CEO of Immunovaccine in 2011, successfully leading the company into clinical development while securing the funding commitments required to advance the company’s lead candidate. Earlier in his career, Mr. Trizzino held leadership roles at several companies with a focus in infectious disease vaccine markets, including MedImmune, LLC (now [AstraZeneca](/org/astrazeneca)), ID Biomedical and Henry Schein, Inc. Mr. Trizzino holds a bachelor of science degree from [Long Island University](/org/long-island-university), CW Post and a master of business administration degree from [New York University](/org/nyu), Stern School of Business.

John J. Trizzino

Ms. Taylor is senior vice president, investor relations and corporate affairs with responsibility for investor relations, public relations, and corporate communications activities at [Novavax](/org/novavax). She brings more than 25 years of communications and commercial leadership to [Novavax](/org/novavax). Most recently, she was vice president of global corporate affairs and communications at [Autolus](/org/autolus) Therapeutics plc, where she led all financial, scientific, and corporate communications. Prior to [Autolus](/org/autolus), Ms. Taylor was senior vice president of global investor relations and corporate affairs at Sucampo. Earlier in her career, she held positions of increasing responsibility at MedImmune LLC, the global biologics arm of [AstraZeneca](/org/astrazeneca), including head of marketing responsible for the commercialization of the company’s respiratory syncytial virus and influenza franchises, as well as roles at [Pfizer](/org/pfizer), where she served in key brand and consumer marketing roles. She has also worked in public relations and communications roles in agency and nonprofit settings. Ms. Taylor earned a master of business administration degree from [Columbia University](/org/columbia-university) and a bachelor of arts degree in foreign affairs from [University of Virginia](/org/university-of-virginia).


Silvia Taylor

Dr. Dubovsky is executive vice president, chief medical officer with responsibility for medical and clinical affairs and related activities at [Novavax](/org/novavax). A recognized leader in vaccine development, Dr. Dubovsky brings more than 20 years of infectious disease experience to [Novavax](/org/novavax). He joined [Novavax](/org/novavax) from [AstraZeneca](/org/astrazeneca), where he was head of clinical engagement and policy and deputy chief medical officer for clinical affairs. Before that, he oversaw the clinical development of early and late-stage infectious disease and vaccine assets at MedImmune, which was subsequently acquired by [AstraZeneca](/org/astrazeneca). Previously, he created and managed a portfolio of 25 malaria vaccine candidates spanning early candidate optimization to Phase 3 clinical studies at PATH’s Malaria Vaccine Initiative. He is the coauthor of more than 50 peer-reviewed scientific publications and currently sits on the board of directors of the Sabin Institute. Dr. Dubovsky earned his master of public health degree from [Johns Hopkins University](/org/johns-hopkins-university) and his doctor of medicine degree from the University of Alabama. He completed his pediatric training at [Stanford University](/org/stanford), his pediatric infectious disease fellowship at the Center for Vaccine Development at the [University of Maryland](/org/university-of-maryland), and his preventive medicine training at [Johns Hopkins University](/org/johns-hopkins-university).

Filip Dubovsky

Mr. Czworka is senior vice president of sales with responsibility for global customer engagement activities. He brings more than two decades of biopharmaceutical experience to [Novavax](/org/novavax), most recently serving as Vice President, Global Customer Engagement at U.S. Pharmacopeia. In sales and marketing leadership positions at [Osiris Therapeutics](/org/osiris-therapeutics), Auxilium Pharmaceuticals, MedImmune and TAP Pharmaceuticals, Mr. Czworka has assembled, developed, deployed and directed award-winning global sales and marketing teams to achieve business objectives. He has launched multiple medications across a variety of therapeutic areas while increasing patient access to vital treatments. Mr. Czworka received a bachelor of science degree in business administration – marketing from the [University of Central Florida](/org/university-of-central-florida).


Frank Czworka

Mr. Lee is senior vice president and chief information officer with responsibility for leading the information technology operations, network infrastructure, enterprise applications, project management, and cybersecurity programs. He works closely with senior management to align IT investments with corporate strategy and business objectives. He joined [Novavax](/org/novavax) in 2017 as senior director of IT with more than 20 years of IT experience, the vast majority of which has been in the life sciences industry. Prior to joining [Novavax](/org/novavax), he served as vice president of cloud solutions at IPDS, Inc., an information technology services company, where he led development and implementation of the cloud solutions portfolio. Mr. Lee previously held positions of increasing responsibility at Human Genome Sciences (HGS) leading up to its acquisition by GlaxoSmithKline (GSK). He led the global IT integration and successfully completed the disposition of all IT assets during the transition of HGS into GSK.

Biegie Lee

Mrs. King joined the [Novavax](/org/novavax) board of directors in 2018. She is the cofounder and chief executive officer of GlycoMimetics, Inc., a clinical-stage biotechnology company. Before founding GlycoMimetics, Inc. in 2003, Mrs. King was an executive in residence at [New Enterprise Associates](/org/new-enterprise-associates) (NEA), one of the nation’s leading venture capital firms. Mrs. King joined NEA after serving as a senior vice president at [Novartis](/org/novartis) Corporation. Before [Novartis](/org/novartis), Mrs. King spent 10 years with Genetic Therapy, Inc. (GTI), through the company’s early stages, initial public offering, and eventual sale to [Novartis](/org/novartis), after which she ran GTI as a wholly owned subsidiary of [Novartis](/org/novartis). Previously, Mrs. King worked at ALZA Corporation and Bain and Company. Mrs. King currently serves on the executive committee of the [Biotechnology Innovation Organization](/org/biotechnology-innovation-organization) (BIO). She also sits on the board of directors of the University of Maryland BioPark. Mrs. King received a bachelors of arts degree from [Dartmouth College](/org/dartmouth) and a master’s degree in business administration from [Harvard Business School](/org/harvard-business-school).


Rachel King

Dr. Mallory is senior vice president, head of clinical development, with leadership responsibility for the clinical development organization and strategic direction of vaccine life-cycle management. He plays a key role in Novavax’ regulatory filings, including the synthesis of clinical data across Novavax’ COVID-19 clinical studies and engagement with global regulatory agencies. Prior to joining the company in 2020, he was Vice President of Clinical Development and the Global Clinical Lead for the COVID-19 and influenza vaccines at AstraZeneca. Earlier, he was a Robert Wood Johnson Clinical Scholar at Johns Hopkins University. Dr. Mallory earned his medical degree from Yale University School Medicine and undergraduate degree from Brown University.

Raburn Mallory

Denny Kim is the SVP, Chief Safety Officer at [Novavax](/org/novavax). Denny has over 15 years of experience in the pharmaceutical industry. 

Denny Kim started their career as a Sr Clinical Trials Physician at Fred Hutchinson Cancer Research Center. Denny then transitioned to Abbott as an Associate Medical Director. In 2009, they joined Takeda Pharmaceuticals as a Medical Director for Pharmacovigilance. In this role, they were responsible for the safety of Takeda’s products and led the clinical research team in US Medical Affairs. Denny left Takeda in 2012 to join [Astellas Pharma](/org/astellas-pharma) as a Senior Medical Director for Pharmacovigilance. After a year at Astellas, they returned to Takeda as the Head Clinical Research in US Medical Affairs. Denny left Takeda in 2017 to join Horizon Pharma plc as their Vice President for Patient Safety and Pharmacovigilance. In 2019, they joined The [Janssen](/org/janssen) Pharmaceutical Companies of [Johnson & Johnson](/org/johnson-johnson) as their TA Matrix Safety Excellence Leader. In this role, they were responsible for the safety of [Janssen](/org/janssen)’s products and led the clinical research team in Infectious Disease and Internal Medicine. Denny left [Janssen](/org/janssen) in 2021 to join [Novavax](/org/novavax) as their SVP, Chief Safety Officer. 

Denny Kim has a proven track record of success in the pharmaceutical industry. Denny is an expert in the field of pharmacovigilance and has extensive experience leading clinical research teams. Denny is a highly skilled physician with a passion for ensuring the safety of patients.

Denny Kim has a BA in Molecular Biophysics and Biochemistry from [Yale University](/org/yale-university), an MD from The University of Chicago Pritzker School of Medicine, and an MPH in Public Health from The Johns Hopkins University.

They work with Rick Crowley - EVP, COO, Seth Toback - Senior Vice President, Global Medical Affiars, and Filip Dubovsky - EVP, Chief Medical Officer. Denny Kim reports to Stanley C. Erck, President & CEO.

Denny Kim

Brian Webb is the SVP of Manufacturing at [Novavax](/org/novavax). Brian has over 20 years of experience in the biotech and pharmaceutical industry. Brian began their career at Human Genome Sciences as a Manager/Sr. Manager of Manufacturing. Brian then spent 11 years at GlaxoSmithKline as the Director of Commercial Manufacturing before joining [Novavax](/org/novavax) in 2014.

Brian Webb completed a Master of Science in Biotechnology at The Johns Hopkins University and a Bachelor of Science in Biology at [Salisbury University](/org/salisbury-university).

They work with and Timothy J. Hahn - SVP, Global Manufacturing Operations. Their manager is Rick Crowley, EVP, COO.

Brian Webb

Ms. McGlynn joined the [Novavax](/org/novavax) board of directors in 2020 and has extensive vaccine industry experience.  She served as president and chief executive officer of the International AIDS Vaccine Initiative (IAVI) from 2011 through 2015, where she led extensive partnership efforts to advance the development, global launch and access to a broadly effective HIV vaccine. Previously, Ms. McGlynn spent more than two decades at [Merck](/org/merck) where she held roles of increasing responsibility, including president of [Merck](/org/merck) Vaccines and Infectious Diseases, and president, U.S. Hospital and Specialty Products Division. She is currently the president and board chair for HCU Network America, a patient advocacy organization focused on the rare genetic disease homocystinuria (HCU) and related disorders. She also serves on the boards of directors of [Amicus Therapeutics](/org/amicus-therapeutics) and [Vertex Pharmaceuticals](/org/vertex-pharmaceuticals) and is a director of the non-profit organization, Life Science Cares Philadelphia. Ms. McGlynn received a bachelor of science degree in pharmacy, a master’s degree in business administration in marketing, and an honorary doctorate from the State University of New York at Buffalo.

Margaret G. Mcglynn

Dr. Young joined the [Novavax](/org/novavax) board of directors in April 2010 and was appointed chairman in April 2011. He has more than 30 years of experience in the fields of molecular genetics, microbiology, immunology, and pharmaceutical development. Most recently, Dr. Young was MedImmune’s president of research and development, where he had responsibility for regulatory affairs and was instrumental in the development of FluMist® and Synagis®. In 2005, Dr. Young was awarded the Albert B. Sabin Humanitarian Award. Prior to MedImmune, Dr. Young was influential in building the department of molecular genetics at Smith Kline & French Laboratories (now part of GlaxoSmithKline) and culminated as director, department of molecular genetics. Dr. Young was on the faculty of the department of microbiology at Mount Sinai School of Medicine in New York City, New York. He received his bachelor of science degrees in biology and general sciences from [Villanova University](/org/villanova-university) and a doctorate in microbiology and immunology from [Baylor College of Medicine](/org/baylor-college-of-medicine) in Houston, Texas.


James F. Young

Mr. McManus joined the [Novavax](/org/novavax) board of directors in 1998. He has served as president, chief executive officer, and director at Misonix, Inc., a medical, scientific, and industrial provider of ultrasonic and air pollution systems, since 1998. Previously, he was president and chief executive officer at New York Bancorp Inc. from 1991 to 1998. From 1990 through November 1991, Mr. McManus was president and chief executive officer at Jamcor Pharmaceuticals Inc. Previously, Mr. McManus served as an assistant to the President of the United States from 1982 to 1985 and held positions with Pfizer Inc. and Revlon Group. Mr. McManus received a BA in economics from the [University of Notre Dame](/org/university-of-notre-dame) and a JD from the Georgetown University Law Center. He served in the US Army Infantry from 1968 through 1970. He is also a recipient of the Ellis Island Medal of Honor.


Michael A. McManus

Mr. Mott is currently a private investor through Mott Family Capital. He serves as chairman of the board for [Adaptimmune](/org/adaptimmune), [Ardelyx](/org/ardelyx), [Epizyme](/org/epizyme), [Imara](/org/imara), and Mersana. From 2008 to 2020, Mr. Mott was general partner at NEA, one of the world’s largest venture capital firms, which invests in companies across all stages in healthcare and technology. Mr. Mott served as president and chief executive officer, vice chairman of MedImmune from 2000 through 2008, during which he led the sale of the company to [AstraZeneca](/org/astrazeneca) in June 2007 for $15.6 billion. He joined MedImmune in 1992 and served in various senior roles during his tenure, including chief operating officer and chief financial officer. During the course of his career, Mr. Mott has been involved in more than $40 billion in corporate acquisitions, fundraising, partnerships, and other capital formation. He has supported more than 35 initial public offerings or corporate acquisitions, brought in more than a dozen new drugs through development to commercialization, and served on 25 corporate boards. Mr. Mott holds a bachelor of arts degree from [Dartmouth College](/org/dartmouth).


David Mott

Dr. Douglas joined the [Novavax](/org/novavax) board of directors in 2010. He has more than 25 years of biotechnology experience having served in corporate development roles at [Genzyme Corporation](/org/genzyme-corporation) since 1989. Most recently, Dr. Douglas was senior vice president of corporate development and a corporate officer at [Genzyme Corporation](/org/genzyme-corporation). As a leader of Genzyme’s corporate development team, Dr. Douglas was involved in numerous acquisitions, licenses, joint ventures, and strategic alliances. From 1982 until its merger with [Genzyme Corporation](/org/genzyme-corporation) in 1989, Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Dr. Douglas was a postdoctoral fellow in Leroy Hood’s laboratory at the [California Institute of Technology](/org/california-institute-of-technology). He received a BS in chemistry from the University of Michigan and a PhD from the University of California, Berkeley in biochemistry. He currently serves on the University of Michigan Technology Transfer National Advisory Board.


Richard Douglas

Gregory M. Glenn

Jill Hoyt is the current EVP, Chief Human Resources Officer at [Novavax](/org/novavax). Prior to this, they were the Director of Human Resources at 3e Technologies International from January 2003 to January 2007. Jill has extensive experience in human resources and is a valuable asset to [Novavax](/org/novavax).

Jill Hoyt has a MA in Human Resource Management from [Marymount University](/org/marymount-university) and a Bachelor's Degree in Business Administration from Shepherd University. Jill also has certification from [SHRM](/org/shrm) in [SHRM](/org/shrm) - Senior Certified Professional (SHRM-SCP) and from [HRCI](/org/hrci) in Senior Professional in Human Resources (SPHR).

They work with Biegie Lee - SVP, CIO, Marco Cacciuttolo - SVP. Process & Analytical Development, and Henrietta Ukwu - SVP, Chief Regulatory & Quality Officer. Jill Hoyt reports to Stanley C. Erck, President & CEO.

Novavax

Org chart

Teams

Leadership Team

CEO and Executive Team

Board of Directors

Discover similar companies